A1AD

(redirected from Alpha-1 antitrypsin deficiency)
Also found in: Medical.
AcronymDefinition
A1ADAlpha-1 Antitrypsin Deficiency (aka AAT deficiency)
References in periodicals archive ?
In addition, POL6014 may show therapeutic benefit for a range of neutrophilic pulmonary diseases with high medical need such as non-cystic fibrosis bronchiectasis, alpha-1 antitrypsin deficiency or primary ciliary dyskinesia.
6 billion, which consists of a portfolio of recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders, and plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions.
Alpha-1 antitrypsin deficiency (AATD) is an inherited condition that produces emphysema along with features of chronic bronchitis.
5) With patients in their 30s or 40s exhibiting signs and symptoms suggestive of COPD, consider a work-up for alpha-1 antitrypsin deficiency.
Some 5,000 COPD patients will be tested to determine the prevalence of Alpha-1 Antitrypsin Deficiency (Alpha-1) in a study marking a major cooperative effort between the Alpha-1 Foundation and the American Association for Respiratory Care (AARC).
Alpha-1 antitrypsin deficiency is a particularly nasty and insidious illness for the one in 10000 children who hit the alpha-1 lottery and develop liver disease.
Talecris produces therapies for chronic rare diseases such as alpha-1 antitrypsin deficiency (alpha-1), primary humoral immunodeficiency disease (PI), and hemophilia.
Key words: alpha-1 antitrypsin deficiency, alpha-1 protease, alpha-1 protease inhibitor, genetic epidemiology, Pi phenotypes, Pi subtypes, population genetics.
The three latest applications to win this status - at the late-March meeting of the Committee - are treatments for emphysema secondary to congenital alpha-1 antitrypsin deficiency, glioma, and oesophageal cancer.
M2 PHARMA-August 23, 2017-Apic Bio to Advance Gene Therapy for Treatment of Alpha-1 Antitrypsin Deficiency
The biopharmaceuticals business, with 2013 annual revenues of approximately $6 billion, consists of a diverse portfolio of recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders, and plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions.
Full browser ?